Results 31 to 40 of about 1,789 (171)

Use of simulated vaginal and menstrual fluids to model in vivo discolouration of silicone elastomer vaginal rings

International Journal of Pharmaceutics: X, 2021
Vaginal rings releasing antiretrovirals – either alone or in combination with contraceptive progestins – are being developed for prevention of human immunodeficiency virus (HIV) transmission via vaginal sex.
Clare F. McCoy, Patrick Spence, Yahya H. Dallal Bashi, Diarmaid J. Murphy, Peter Boyd, Bindi Dangi, Tiffany Derrick, Bríd Devlin, Kyle Kleinbeck, R. Karl Malcolm   +9 more
doaj   +1 more source

Correlates of Dapivirine Vaginal Ring Acceptance among Women Participating in an Open Label Extension Trial. [PDF]

AIDS Behav, 2023
MTN-025/HOPE was an open-label trial of the dapivirine vaginal ring conducted in four African countries between 2016 and 2018. Women were first offered one ring monthly (at baseline, months 1 and 2), thereafter, transitioned to a more applicable real-world dispensation schedule, - 3 rings quarterly (at months 3, 6 and 9).
Mirembe BG, Cabrera MV, van der Straten A, Nakalega R, Cobbing M, Mgodi NM, Palanee-Phillips T, Mayo AJ, Dadabhai S, Mansoor LE, Siva S, Nair G, Chinula L, Akello CA, Nakabiito C, Soto-Torres LE, Baeten JM, Brown ER.   +17 more
europepmc   +3 more sources

Promises and potential pitfalls of long-acting injectable pre-exposure prophylaxis

Southern African Journal of HIV Medicine, 2023
The number of products that can provide pre-exposure prophylaxis (PrEP) for HIV prevention is expanding, with three now approved in South Africa (oral Tenofovir-based PrEP, injectable Cabotegravir, and a Dapivirine-based vaginal ring) and more in the ...
Carey Pike, Elzette Rousseau, Linda-Gail Bekker   +2 more
doaj   +1 more source

Men's Sexual Experiences with the Dapivirine Vaginal Ring in Malawi, South Africa, Uganda and Zimbabwe. [PDF]

AIDS Behav, 2021
The dapivirine vaginal ring has been well-tolerated and shown to prevent HIV in clinical trials. The ring is female initiated, yet endorsement for use is sought from male partners in many relationships. In clinical studies, participants have expressed worries about men detecting rings during vaginal sex, which introduces concerns about product use ...
Montgomery ET, Katz AWK, Duby Z, Mansoor LE, Morar NS, Naidoo K, Tsidya M, Chitukuta M, Guma V, Tenza S, Leslie J, Garcia M, Naidoo S.   +12 more
europepmc   +4 more sources

Acceptability and use of a dapivirine vaginal ring in a phase III trial [PDF]

AIDS, 2017
The MTN-020/ASPIRE trial evaluated the safety and effectiveness of the dapivirine vaginal ring for prevention of HIV-1 infection among African women. A nested qualitative component was conducted at six of 15 study sites in Uganda, Malawi, Zimbabwe and South Africa to evaluate acceptability of and adherence to the ring.Qualitative study participants (n =
Elizabeth T, Montgomery, Ariane, van der Straten, Miria, Chitukuta, Krishnaveni, Reddy, Kubashni, Woeber, Millicent, Atujuna, Linda-Gail, Bekker, Juliane, Etima, Teopista, Nakyanzi, Ashley J, Mayo, Ariana, Katz, Nicole, Laborde, Cynthia I, Grossman, Lydia, Soto-Torres, Thesla, Palanee-Phillips, Jared M, Baeten   +15 more
openaire   +4 more sources

HIV prevention at drug shops: awareness and attitudes among shop dispensers and young women about oral pre-exposure prophylaxis and the dapivirine ring in Shinyanga, Tanzania

AIDS Research and Therapy, 2021
Background HIV risk remains high among adolescent girls and young women (AGYW, ages 15–24) in Tanzania. Many AGYW experience stigma and provider bias at health facilities, deterring their use of HIV prevention services.
Julia Tubert, Laura Packel, Lauren A. Hunter, Rashid Mfaume, Prosper Njau, Angela A. Ramadhani, Jenny X. Liu, Sandra I. McCoy   +7 more
doaj   +1 more source

Women's motivations for participating in the dapivirine vaginal ring open label extension study. [PDF]

AIDS Care, 2023
Open-Label Extension (OLE) studies are important in the drug development process and are used to further support the licensing applications and regulatory approvals of products. We aimed to understand why women chose to join the HOPE OLE study - where women were offered the dapivirine vaginal ring after two pivotal trials were completed - through data ...
Naidoo K, Montgomery ET, Katz AWK, Garcia M, Naidoo S, Mansoor LE.   +5 more
europepmc   +3 more sources

WHO guidance grounded in a comprehensive approach to sexual and reproductive health and human rights: topical pre-exposure prophylaxis [PDF]

, 2014
Introduction: Two new microbicide products based on topical (vaginal) application of antiretroviral drugs – 1% tenofovir gel and the dapivirine ring – are currently in late-stage clinical testing, and results on their safety and effectiveness are ...
Elizabeth McGrory, Fourth World Conference on Women, Gray, Manjula Lusti-Narasimhan, Marleen Temmerman, Marrazzo, Plan of Action of the International Conference, Rachel Baggaley, Rajat Khosla, The President's Emergency Plan for AIDS Relief, Tim Farley, World Health Organization, World Health Organization, World Health Organization   +13 more
core   +8 more sources

Reasons for nonadherence to the dapivirine vaginal ring: narrative explanations of objective drug-level results. [PDF]

AIDS, 2018
MTN-020/ASPIRE trial and IPM-027/Ring Study recently proved the dapivirine vaginal ring was safe and effective with consistent use. To optimize the ring's impact, the barriers and facilitators to ring adherence must be understood and addressed.Former ASPIRE participants were stratified by age group (18-21; 22-45) and randomly selected at seven sites in
Montgomery ET, Stadler J, Naidoo S, Katz AWK, Laborde N, Garcia M, Reddy K, Mansoor LE, Etima J, Zimba C, Chitukuta M, Soto-Torres L.   +11 more
europepmc   +4 more sources

Physiologically‐based pharmacokinetic model of vaginally administered dapivirine ring and film formulations [PDF]

British Journal of Clinical Pharmacology, 2018
AimsA physiologically‐based pharmacokinetic (PBPK) model of the vaginal space was developed with the aim of predicting concentrations in the vaginal and cervical space. These predictions can be used to optimize the probability of success of vaginally administered dapivirine (DPV) for HIV prevention.
Katherine Kay, Dhaval K. Shah, Lisa Rohan, Robert Bies   +3 more
openaire   +2 more sources